December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

126.52 +2.12 (+1.70%)
Streaming Delayed Price Updated: 3:35 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
News headline image
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
News headline image
For Hedge Funds, This Is The Worst 6 Months Since The Financial Crisis: Here's Why ↗
The most popular hedge fund positions have fared exceptionally poorly in recent months. The core issues behind recent (and continuing) hedge fund underperformance: concentration, crowding and... 
Via Talk Markets
News headline image
Week In Review: Sino Biological Stages $772 Million IPO On ChiNext Exchange ↗
Sino Biological​​​, a Beijing company that offers biological research reagents to global markets, completed a $772 million IPO on Shenzhen's ChiNext Exchange. On the first day of trading, the stock... 
Via Talk Markets
Topics Initial Public Offering
News headline image
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
BriaCell, ImaginAb Join Forces To Assess Imaging Tech In Breast Cancer Trial ↗
BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation... 
Via Benzinga
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China ↗
Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater... 
Via Benzinga
News headline image
Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China
From Incyte
Via Business Wire
News headline image
BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies ↗
Photo by Chokniti Khongchum from Pexels In 2020, there were 2.3 million women globally diagnosed with breast cancer and 685,000 deaths, according to the World Health Organization... 
Via Benzinga
Topics Death
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Before 10 a.m. ET on Tuesday, 60 companies set new 52-week lows. Key Facts: PACCAR (NASDAQ:PCAR) was the biggest company by market cap to set a new 52-week low.... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
Is the PD-(L)1 Party Over After Incyte's FDA Rejection? ↗
There's definitely already a crowded market for PD-1 and PD-L1 immunotherapies. 
Via The Motley Fool
News headline image
Incyte Corporation (INCY) Q2 2021 Earnings Call Transcript ↗
INCY earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
A Perspective On The Upcoming Calithera Cystic Fibrosis Read-Out ↗
Calithera is guiding for the market to expect what we believe will be a key data read-out in Q3 from its ongoing CB-280 study involving Cystic Fibrosis. A positive read-out here could see a significant... 
Via Talk Markets
News headline image
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates ↗
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
News headline image
A Preview Of Incyte's Earnings ↗
Incyte (NASDAQ:INCY) will be releasing its next round of earnings this Tuesday, August 03. For all of the relevant information, here is your guide for Tuesday's Q2 earnings... 
Via Benzinga
News headline image
2 Stocks Under $100 You Can Buy and Hold Forever ↗
Drugmakers can be excellent long-term holdings. 
Via The Motley Fool
News headline image
Eli Lilly-Incyte's Rheumatoid Arthritis Drug Gets OK From FDA For Solo Use In Hospitalized COVID-19 Patients ↗
The FDA extended the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) rheumatoid... 
Via Benzinga
News headline image
FDA Strikes Off Incyte's Retifanlimab Application In Anal Cancer ↗
The 
Via Benzinga
News headline image
Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
From Incyte Corporation
Via Business Wire
News headline image
Benchmark Upgrades Incyte After Stock Selloff ↗
The recent downturn in Incyte Corporation’s (NASDAQ:INCY... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021 ↗
Upgrades For Bank of Marin Bancorp (NASDAQ: 
Via Benzinga
News headline image
AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA ↗
AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market.... 
Via Benzinga
News headline image
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
News headline image
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,... 
Via Benzinga
Topics Product Recall
News headline image
Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients ↗
Incyte Corporation (NASDAQ: INCY) has announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM... 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.